Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience.
Altamura C, Brunelli N, Marcosano M, Aurilia C, Egeo G, Lovati C, Favoni V, Perrotta A, Maestrini I, Schiano Di Cola F, d'Onofrio F, Finocchi C, Bertuzzo D, Bono F, Ranieri A, Albanese M, Messina R, Doretti A, Di Piero V, Cevoli S, Barbanti P, Vernieri F; GARLIT Study Group. Altamura C, et al. Among authors: schiano di cola f. J Neurol. 2022 Nov;269(11):5848-5857. doi: 10.1007/s00415-022-11226-4. Epub 2022 Jun 28. J Neurol. 2022. PMID: 35763113 Free PMC article.
Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study.
Schiano di Cola F, Rao R, Caratozzolo S, Di Cesare M, Venturelli E, Balducci U, Sidoti V, Pari E, Costanzi C, di Summa A, Sixt GJ, D'Adda E, Liberini P, Padovani A. Schiano di Cola F, et al. Among authors: di summa a, di cesare m. Neurol Sci. 2020 Dec;41(Suppl 2):489-490. doi: 10.1007/s10072-020-04670-5. Neurol Sci. 2020. PMID: 32856234 No abstract available.
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study.
Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Lovati C, Bertuzzo D, d'Onofrio F, Doretti A, Di Fiore P, Finocchi C, Schiano Di Cola F, Ranieri A, Colombo B, Bono F, Albanese M, Cevoli S, Barbanti P; GARLIT Study Group. Vernieri F, et al. Among authors: schiano di cola f, di fiore p. Eur J Neurol. 2022 Apr;29(4):1198-1208. doi: 10.1111/ene.15197. Epub 2021 Dec 6. Eur J Neurol. 2022. PMID: 34826192
CGRP-monoclonal antibodies and SARS-CoV-2 vaccination.
Schiano di Cola F, Caratozzolo S, Liberini P, Padovani A, Rao R. Schiano di Cola F, et al. J Neurol. 2022 Jun;269(6):2848-2849. doi: 10.1007/s00415-021-10946-3. Epub 2022 Jan 8. J Neurol. 2022. PMID: 34999961 Free PMC article. No abstract available.
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients.
Schiano di Cola F, Caratozzolo S, Bolchini M, Ceccardi G, Cortinovis M, Liberini P, Padovani A, Rao R. Schiano di Cola F, et al. Neurol Sci. 2022 Sep;43(9):5763-5764. doi: 10.1007/s10072-022-06154-0. Epub 2022 May 26. Neurol Sci. 2022. PMID: 35618933 Free PMC article. No abstract available.
19 results